Can precision psychiatry finally move beyond trial and error?

The Foundation for the National Institutes of Health's Multi-Modal Assessment and Phenotyping in Depression (MAP-D) initiative aims to use advanced data integration and AI to identify biological subtypes of depression, enabling precision psychiatry based on biology rather than symptoms. This could improve patient stratification, biomarker discovery, and clinical trial design in depression treatment.

This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.